Home /Biblio

Biblio

Found 361 results
Author Keyword Title Type [ Year(Asc)]
2020
X. Paoletti, Lewsley, L. - A., Daniele, G., Cook, A., Yanaihara, N., Tinker, A., Kristensen, G., Ottevanger, P. B., Aravantinos, G., Miller, A., Boere, I. A., Fruscio, R., Reyners, A. K. L., Pujade-Lauraine, E., Harkin, A., Pignata, S., Kagimura, T., Welch, S., Paul, J., Karamouza, E., and Glasspool, R. M., “Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.”, JAMA Netw Open, vol. 3, no. 1, p. e1918939, 2020.
2019
G. F. Vercellino, Erdemoglu, E., Lichtenberg, P., Muallem, M. Z., Richter, R., Abu-Rustum, N. R., Plante, M., Lécuru, F., Greggi, S., Monk, B. J., Sagae, S., Denkert, C., Keller, M., Alhakeem, M., Hellriegel, M., Dückelmann, A. M., Chiantera, V., and Sehouli, J., “A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer.”, Arch Gynecol Obstet, 2019.
M. Bagnoli, Shi, T. Yan, Gourley, C., Speiser, P., Reuss, A., Nijman, H. W., Creutzberg, C. L., Scholl, S., Negrouk, A., Brady, M. F., Hasegawa, K., Oda, K., McNeish, I. A., Kohn, E. C., Oza, A. M., MacKay, H., Millan, D., Bennett, K., Scott, C., and Mezzanzanica, D., “Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.”, Cells, vol. 8, no. 3, 2019.
2018
S. M. de Boer, Powell, M. E., Mileshkin, L. R., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. - H., Jürgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D. M., Hanzen, C., Lutgens, L. C. H. W., Smit, V. T. H. B. M., Singh, N., Do, V., D'Amico, R., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H., and Creutzberg, C. L., “Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.”, Lancet Oncol, 2018.
S. C. Dowdy and Glaser, G. E., “Adjuvant therapy for women with high-risk endometrial carcinoma.”, Lancet Oncol, 2018.
V. D. Gonzalez, Samusik, N., Chen, T. J., Savig, E. S., Aghaeepour, N., Quigley, D. A., Huang, Y. - W., Giangarrà, V., Borowsky, A. D., Hubbard, N. E., Chen, S. - Y., Han, G., Ashworth, A., Kipps, T. J., Berek, J. S., Nolan, G. P., and Fantl, W. J., “Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.”, Cell Rep, vol. 22, no. 7, pp. 1875-1888, 2018.
M. Leonard Friedlander, Rau, J., Lee, C. Khoon, Meier, W., Lesoin, A., Kim, J. - W., Poveda, A. M., Buck, M., Scambia, G., Shimada, M., Hilpert, F., King, M. Trudy, Debruyne, P., Bologna, A., Malander, S., Monk, B. J., Petru, E., Calvert, P., Herzog, T. J., Barrett, C., and A Bois, du, “Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial.”, Ann Oncol, vol. 29, no. 3, pp. 737-743, 2018.
D. K. Gaffney, Hashibe, M., Kepka, D., Maurer, K. A., and Werner, T. L., “Too many women are dying from cervix cancer: Problems and solutions.”, Gynecol Oncol, 2018.
2017
W. Small, Bacon, M., Bajaj, A., Chuang, L. T., Fisher, B. J., Harkenrider, M. M., Jhingran, A., Kitchener, H. C., Mileshkin, L. R., Viswanathan, A., and Gaffney, D. K., “Cervical cancer: A global health crisis.”, Cancer, vol. 123, no. 13, pp. 2404-2412, 2017.
M. A. Bookman, Okamoto, A., Stuart, G. C. E., Yanaihara, N., Aoki, D., Bacon, M., Fujiwara, K., González-Martín, A., Harter, P., Kim, J. W., Ledermann, J. A., Pujade-Lauraine, E., Quinn, M., and Ochiai, K., “Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.”, Ann Oncol, vol. 28, no. suppl_8, pp. viii30-viii35, 2017.
G. C. E. Stuart, Kitchener, H. C., Vermorken, J. B., Quinn, M., Small, W., Pujade-Lauraine, E., Chou, H., Wong, M., and Bacon, M., “The Impact of an International Network (Gynecologic Cancer InterGroup) for Clinical Research on Global Capacity for Gynecologic Cancer Clinical Trials.”, Int J Gynecol Cancer, 2017.
2016
S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H. C., Nam, B. - H., Jhingran, A., Temkin, S., Mileshkin, L. R., Berns, E. M. J. J., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., “Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.”, Int J Gynecol Cancer, vol. 26, no. 1, p. 207, 2016.
P. Harter, Johnson, T., Berton-Rigaud, D., Park, S. - Y., Friedlander, M. Leonard, Del Campo, J. M., Shimada, M., Forget, F., Mirza, M. R., Colombo, N., Zamagni, C., Chan, J. K., Imhof, M., Herzog, T. J., O'Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., Jobanputra, M., Xu, C. - F., and du Bois, A., “BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.”, Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.
J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M. Leonard, Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A. D., Kaplan, R. S., and Parmar, M. K. B., “Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.
D. J. Pulford, Harter, P., Floquet, A., Barrett, C., Suh, D. Hoon, Friedlander, M. Leonard, Arranz, J. Angel, Hasegawa, K., Tada, H., Vuylsteke, P., Mirza, M. R., Donadello, N., Scambia, G., Johnson, T., Cox, C., Chan, J. K., Imhof, M., Herzog, T. J., Calvert, P., Wimberger, P., Berton-Rigaud, D., Lim, M. Cheol, Elser, G., Xu, C. - F., and Bois, Adu, “Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.”, BMC Med Ethics, vol. 17, no. 1, p. 63, 2016.
A. M. Angarita, Johnson, C. Alonia Lil, Fader, A. Nickles, and Christianson, M. S., “Fertility preservation: A key survivorship issue for young women with cancer ”, Frontiers in Oncology , vol. 6, no. 102, 2016.
S. Lheureux, Karakasis, K., Harter, P., Scott, C., Bacon, M., Bryce, J., Le Fur, N., Pujade-Lauraine, E., and Oza, A. M., “Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.”, Gynecol Oncol, vol. 140, no. 1, p. 94, 2016.
K. Katherine, Julia, B., Valerie, B., Oza, A. M., and Stephanie, L., “Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention ”, Frontiers in Oncology , vol. 6, no. 00119 , 2016.
Y. Ikeda, Furusawa, A., Kitagawa, R., Tokinaga, A., Ito, F., Ukita, M., Nomura, H., Yamagami, W., Tanabe, H., Mikami, M., Takeshima, N., and Yaegashi, N., “Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan.”, J Gynecol Oncol, vol. 27, no. 3, p. e29, 2016.
K. Harano, Hirakawa, A., Yunokawa, M., Nakamura, T., Satoh, T., Nishikawa, T., Aoki, D., Ito, K., Ito, K., Nakanishi, T., Susumu, N., Takehara, K., Watanabe, Y., Watari, H., and Saito, T., “Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.”, Int J Clin Oncol, vol. 21, no. 1, pp. 168-76, 2016.
L. Brotto, Brundage, M., Hoskins, P., Vergote, I. B., Cervantes, A., Casado, H. A., Poveda, A. M., Eisenhauer, E., and Tu, D., “Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.”, Support Care Cancer, vol. 24, no. 3, p. 1249, 2016.
S. Temkin, Tanner, E. J., Dewdney, S., and Minasian, L. M., “Reducing overtreatment in gynecologic oncology: the case for less in endometrial and ovarian cancer”, Frontiers in Oncology , vol. 6, no. 00118 , 2016.
A. du Bois, Kristensen, G. B., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I. B., Del Campo, J. M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., Scambia, G., Meier, W., Nicoletto, M. O., Bjørge, L., Lortholary, A., Sailer, M. Oliver, Merger, M., and Harter, P., “Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.”, Lancet Oncol, vol. 17, no. 1, p. 89, 2016.
J. K. Chan, Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H., and Monk, B. J., “Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.”, N Engl J Med, vol. 374, no. 8, p. 748, 2016.
2015
F. T. Roncolato, O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P. P., Oza, A. M., Åvall-Lundqvist, E., Berek, J. S., Sjoquist, K. Marie, Gillies, K., Butow, P., Stockler, M. R., King, M. Trudy, and Friedlander, M. Leonard, “Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The GCIG Symptom Benefit Study (SBS).”. 2015.

Pages